|
|||||
|
|
Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma |
|
| Authors: | Giorgio Walter Canonica Johann Christian Virchow Petra Zieglmayer Christian Ljørring Ida Mosbech Smith Holger Mosbech |
| Affiliation: | 1. Allergy &2. Respiratory Diseases Clinic, DIMI, University of Genova, Genova, Italycanonica@unige.it;4. Department of Pneumology/Intensive Care Medicine, University of Rostock, Rostock, Germany;5. Allergy Center Vienna West, Vienna Challenge Chamber, Vienna, Austria;6. Global Clinical Development, ALK, H?rsholm, Denmark;7. Allergy Clinic, Copenhagen University Hospital Gentofte, Hellerup, Denmark |
| Abstract: | Introduction: In the treatment of house dust mite (HDM) respiratory allergic disease, allergy immunotherapy constitutes an add-on treatment option targeting the underlying immunological mechanisms of allergic disease. However, for the treatment of HDM allergic asthma, the use of subcutaneous allergy immunotherapy (SCIT) has been limited by the risk of systemic adverse events. Thus, sublingually administered allergy immunotherapy (SLIT) has been investigated as a treatment option with an improved tolerability profile that allows for safer treatment of patients with HDM allergic asthma. Areas covered: In this Drug Profile, we provide a review of the clinical data behind the SQ HDM SLIT-tablet, which was recently approved for the treatment of HDM allergic asthma and allergic rhinitis by regulatory authorities in several European countries. Expert commentary: The SQ HDM SLIT-tablet is the first allergy immunotherapy to be tested prospectively in patients with asthma, and to favorably modify patient relevant end points such as requirement for inhaled corticosteroid (ICS) or the time to first asthma exacerbation upon ICS reduction, suggesting that SQ HDM SLIT-tablet treatment may contribute to improving overall asthma control. |
| Keywords: | House dust mite allergy immunotherapy sublingual immunotherapy (SLIT) SLIT-tablet allergic asthma |